Phase 4
Completed N=62
Safety and Efficacy of LATISSE® in the Augmentation of Eyelashes of Korean Subjects
Eyelash Hypotrichosis
Source: ClinicalTrials.gov NCT01229423 ↗
Enrolled (actual)
62
Serious AEs
0.0%
Results posted
Jan 2012
Primary outcomePrimary: Change From Baseline in Eyelash Length at Week 20 — 5.92; 1.10 Millimeter (mm)
Summary
This study will evaluate the safety and efficacy of LATISSE® (bimatoprost 0.03%) in the augmentation of eyelashes in Korean women.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Change From Baseline in Eyelash Length at Week 20 |
5.92; 1.10 | — |
| SECONDARY Percentage of Subjects With an Improvement of at Least 1-Point in Global Eyelash Assessment (GEA) Score at Week 20 |
81.4 | — |
| SECONDARY Change From Baseline in Eyelash Thickness at Week 20 |
1.39; 0.25 | — |
| SECONDARY Change From Baseline in Eyelash Intensity (Darkness) at Week 20 |
140.02; -12.97 | — |
| SECONDARY Percentage of Subjects With an Improvement in Satisfaction With Overall Eyelash Prominence at Week 20 |
83.05 | — |
| SECONDARY Percentage of Subjects Satisfied With Treatment at Week 20 |
83.1 | — |
Eligibility Criteria
Inclusion Criteria
- Eyelash prominence assessment of minimal or moderate
- Of Korean ethnicity
Exclusion Criteria
- Any eye disease or abnormality
- Any ocular surgery or use of any eyelash extension or eyelash growth products within 3 months
- Any permanent eyeliner within 5 years
- Eyelash implants of any kind
- Eyelash tint or dye application within 2 months
- Use of any treatment that may affect hair growth within 6 months
Data sourced from ClinicalTrials.gov (NCT01229423). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.